JP2018512162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512162A5 JP2018512162A5 JP2017554057A JP2017554057A JP2018512162A5 JP 2018512162 A5 JP2018512162 A5 JP 2018512162A5 JP 2017554057 A JP2017554057 A JP 2017554057A JP 2017554057 A JP2017554057 A JP 2017554057A JP 2018512162 A5 JP2018512162 A5 JP 2018512162A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- dna
- cell
- sequence
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 94
- 210000004027 cell Anatomy 0.000 claims description 91
- 108020004414 DNA Proteins 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 230000004048 modification Effects 0.000 claims description 26
- 238000012986 modification Methods 0.000 claims description 26
- 238000001890 transfection Methods 0.000 claims description 21
- 230000003213 activating effect Effects 0.000 claims description 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 10
- 238000004520 electroporation Methods 0.000 claims description 8
- 101710163270 Nuclease Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 210000004986 primary T-cell Anatomy 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 108020005004 Guide RNA Proteins 0.000 claims description 2
- 108010061833 Integrases Proteins 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 238000010459 TALEN Methods 0.000 claims description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 2
- 102000008579 Transposases Human genes 0.000 claims description 2
- 108010020764 Transposases Proteins 0.000 claims description 2
- 238000002617 apheresis Methods 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 238000011031 large-scale manufacturing process Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003833 cell viability Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 102000012330 Integrases Human genes 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146618P | 2015-04-13 | 2015-04-13 | |
| US62/146,618 | 2015-04-13 | ||
| PCT/US2016/027253 WO2016168275A1 (en) | 2015-04-13 | 2016-04-13 | Methods and compositions for modifying genomic dna |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512162A JP2018512162A (ja) | 2018-05-17 |
| JP2018512162A5 true JP2018512162A5 (cg-RX-API-DMAC7.html) | 2019-05-23 |
| JP6885876B2 JP6885876B2 (ja) | 2021-06-16 |
Family
ID=55806847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554057A Active JP6885876B2 (ja) | 2015-04-13 | 2016-04-13 | ゲノムｄｎａを改変するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11608511B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3283635B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6885876B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20170135966A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107980059B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2982759C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2926467T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016168275A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| EP3555273B1 (en) | 2016-12-16 | 2024-05-22 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| LT3645719T (lt) | 2017-06-30 | 2022-05-25 | Inscripta, Inc. | Automatinio ląstelių apdorojimo būdai, moduliai, priemonės ir sistemos |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US10738327B2 (en) | 2017-08-28 | 2020-08-11 | Inscripta, Inc. | Electroporation cuvettes for automation |
| KR102296580B1 (ko) | 2017-09-01 | 2021-09-02 | 론자 워커스빌 아이엔씨. | 엔드-투-엔드 세포 요법의 자동화 |
| US10443074B2 (en) | 2017-09-30 | 2019-10-15 | Inscripta, Inc. | Modification of cells by introduction of exogenous material |
| AU2019241967A1 (en) | 2018-03-29 | 2020-11-19 | Inscripta, Inc. | Automated control of cell growth rates for induction and transformation |
| WO2019200004A1 (en) | 2018-04-13 | 2019-10-17 | Inscripta, Inc. | Automated cell processing instruments comprising reagent cartridges |
| US10501738B2 (en) | 2018-04-24 | 2019-12-10 | Inscripta, Inc. | Automated instrumentation for production of peptide libraries |
| US10526598B2 (en) | 2018-04-24 | 2020-01-07 | Inscripta, Inc. | Methods for identifying T-cell receptor antigens |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| US11760983B2 (en) | 2018-06-21 | 2023-09-19 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US10533152B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US10532324B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| AU2019363487A1 (en) | 2018-08-30 | 2021-04-15 | Inscripta, Inc. | Improved detection of nuclease edited sequences in automated modules and instruments |
| CN112752847B (zh) | 2018-09-28 | 2025-03-28 | 奥克泰生物科技股份有限公司 | 磁性分离 |
| EP3870697A4 (en) | 2018-10-22 | 2022-11-09 | Inscripta, Inc. | GMO ENZYMES |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| US11714096B2 (en) | 2018-12-21 | 2023-08-01 | Octane Biotech Inc. | Carousel for modular biologic production units |
| US11718833B2 (en) | 2018-12-21 | 2023-08-08 | Lonza Walkersville, Inc. | Automated production of viral vectors |
| CN113498432A (zh) | 2019-02-08 | 2021-10-12 | 隆萨沃克斯维尔股份有限公司 | 用于自动化生物反应器的细胞浓缩方法和装置 |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| EP3947691A4 (en) | 2019-03-25 | 2022-12-14 | Inscripta, Inc. | SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST |
| EP3953477A4 (en) | 2019-06-06 | 2022-06-22 | Inscripta, Inc. | HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING |
| AU2020297499A1 (en) | 2019-06-21 | 2022-02-03 | Inscripta, Inc. | Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli |
| US10927385B2 (en) | 2019-06-25 | 2021-02-23 | Inscripta, Inc. | Increased nucleic-acid guided cell editing in yeast |
| CA3158797A1 (en) | 2019-10-24 | 2021-04-29 | Octane Biotech Inc. | Cell culture chamber with improved cell-contacting surfaces |
| CA3159567A1 (en) | 2019-11-11 | 2021-05-20 | Lonza Walkersville, Inc. | Quality control methods for automated cell processing |
| US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| AU2020402526B2 (en) | 2019-12-10 | 2025-01-23 | Inscripta, Inc. | Novel MAD nucleases |
| US10704033B1 (en) | 2019-12-13 | 2020-07-07 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CN114829607A (zh) | 2019-12-18 | 2022-07-29 | 因思科瑞普特公司 | 用于体内检测核酸引导的核酸酶编辑的细胞的Cascade/dCas3互补测定 |
| US10689669B1 (en) | 2020-01-11 | 2020-06-23 | Inscripta, Inc. | Automated multi-module cell processing methods, instruments, and systems |
| US11225674B2 (en) | 2020-01-27 | 2022-01-18 | Inscripta, Inc. | Electroporation modules and instrumentation |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| US11299731B1 (en) | 2020-09-15 | 2022-04-12 | Inscripta, Inc. | CRISPR editing to embed nucleic acid landing pads into genomes of live cells |
| CN112195193A (zh) * | 2020-09-30 | 2021-01-08 | 上海交通大学 | 单链dna在基因转染中的应用 |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| AU2021415461A1 (en) | 2021-01-04 | 2023-08-17 | Inscripta, Inc. | Mad nucleases |
| WO2022150269A1 (en) | 2021-01-07 | 2022-07-14 | Inscripta, Inc. | Mad nucleases |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| DE69128350T2 (de) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| JPH08511680A (ja) | 1993-03-23 | 1996-12-10 | シービーアール・ラボラトリーズ・インコーポレーテツド | 細胞内への生物学的活性物質の封入のための方法および装置 |
| JPH0844143A (ja) | 1993-06-29 | 1996-02-16 | Toshiba Corp | 帯電装置並びに該帯電装置を備えた画像形成装置 |
| CA2214800C (en) | 1995-03-10 | 2002-01-22 | Entremed, Inc. | Flow electroporation chamber and method |
| US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
| US6074605A (en) | 1995-03-10 | 2000-06-13 | Entremed, Inc. | Flow electroporation chamber and method |
| US5720921A (en) | 1995-03-10 | 1998-02-24 | Entremed, Inc. | Flow electroporation chamber and method |
| US7067318B2 (en) * | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| EP0824594B1 (en) * | 1995-05-04 | 2005-04-06 | The United States of America as Representend by The Secretary of the Navy | Improved methods for transfecting t cells |
| US6090617A (en) | 1996-12-05 | 2000-07-18 | Entremed, Inc. | Flow electroporation chamber with electrodes having a crystalline metal nitride coating |
| JP4082740B2 (ja) | 1997-02-28 | 2008-04-30 | キリンファーマ株式会社 | 内因性遺伝子が破壊されている分化多能性保持細胞 |
| WO2002022834A2 (en) | 2000-09-15 | 2002-03-21 | Deltagen, Inc. | Methods of producing cells and animals comprising targeted gene modifications |
| WO2002026966A2 (en) | 2000-09-29 | 2002-04-04 | Ecole Polytechnique Federale De Lausanne | Transfection using plasmid preparations |
| US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
| DK1456345T3 (en) * | 2001-08-22 | 2016-09-26 | Maxcyte Inc | Apparatus and method for electroporation of biological samples |
| EP1565555A4 (en) | 2002-09-30 | 2008-07-09 | Maxcyte Inc | DEVICE AND METHOD FOR STRETCH ELECTROPORATION |
| JP2006518219A (ja) | 2003-02-18 | 2006-08-10 | マックスサイト インコーポレーティッド | 電気穿孔法による細胞への抗原の負荷方法 |
| US8409861B2 (en) * | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| WO2005113820A2 (en) | 2004-05-12 | 2005-12-01 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
| US7531327B2 (en) | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
| WO2007015691A2 (en) | 2004-07-23 | 2007-02-08 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
| US20070059833A1 (en) | 2005-09-07 | 2007-03-15 | Maxcyte, Inc. | Use of Nucleases to Improve Viability and Enhance Transgene Expression in Transfected Cells |
| KR101087809B1 (ko) | 2006-04-10 | 2011-11-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 단일 세포 및 콜로니의 수집을 위한 시스템 |
| WO2008153742A2 (en) | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
| WO2012001073A2 (en) | 2010-07-01 | 2012-01-05 | Glaxo Group Limited | Improved method for selecting high producing cell lines |
| SG187075A1 (en) | 2010-07-23 | 2013-03-28 | Sigma Aldrich Co Llc | Genome editing using targeting endonucleases and single-stranded nucleic acids |
| AU2012328682B2 (en) | 2011-10-27 | 2017-09-21 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the HPRT locus |
| WO2013139994A1 (en) | 2012-03-23 | 2013-09-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | A novel method of producing an oocyte carrying a modified target sequence in its genome |
| AU2013259647B2 (en) * | 2012-05-07 | 2018-11-08 | Corteva Agriscience Llc | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| MX2014015204A (es) | 2012-06-12 | 2015-08-07 | Genentech Inc | Metodos y composiciones para generar alelos con inactivacion condicional. |
| CN102839214A (zh) | 2012-09-06 | 2012-12-26 | 许汉鹏 | 筛选真核细胞基因组内特定基因调控相关机制和分子的方法 |
| JP6401704B2 (ja) * | 2012-10-10 | 2018-10-10 | サンガモ セラピューティクス， インコーポレイテッド | Ｔ細胞を修飾する化合物およびその使用 |
| DK2970915T3 (da) | 2013-03-15 | 2019-11-11 | Maxcyte Inc | Fremgangsmåder og sammensætninger til generering af stabile transficerede celler |
| CN103224947B (zh) * | 2013-04-28 | 2015-06-10 | 陕西师范大学 | 一种基因打靶系统 |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| WO2015160683A1 (en) | 2014-04-14 | 2015-10-22 | Maxcyte, Inc. | Methods and compositions for modifying genomic dna |
| EP3188763B1 (en) | 2014-09-02 | 2020-05-13 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification |
-
2016
- 2016-04-13 KR KR1020177032721A patent/KR20170135966A/ko not_active Ceased
- 2016-04-13 WO PCT/US2016/027253 patent/WO2016168275A1/en not_active Ceased
- 2016-04-13 US US15/566,320 patent/US11608511B2/en active Active
- 2016-04-13 CN CN201680031891.4A patent/CN107980059B/zh active Active
- 2016-04-13 ES ES16718143T patent/ES2926467T3/es active Active
- 2016-04-13 CA CA2982759A patent/CA2982759C/en active Active
- 2016-04-13 EP EP16718143.7A patent/EP3283635B1/en active Active
- 2016-04-13 JP JP2017554057A patent/JP6885876B2/ja active Active
- 2016-04-13 KR KR1020257013453A patent/KR20250058073A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512162A5 (cg-RX-API-DMAC7.html) | ||
| US20250333468A1 (en) | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene | |
| JP2017513477A5 (cg-RX-API-DMAC7.html) | ||
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| US12344656B2 (en) | Genetically engineered T cells having improved persistence in culture | |
| KR20230074515A (ko) | 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포 | |
| WO2022113056A1 (en) | Gene-edited natural killer cells | |
| JP2023524976A (ja) | 必須遺伝子ノックインによる選択 | |
| WO2016071513A1 (en) | Improved method for the generation of genetically modified cells | |
| Basar et al. | Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells | |
| US20230083383A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| JP2022550599A (ja) | 操作されたデュアルガイド核酸を有するｃｒｉｓｐｒシステム | |
| EP4419672A2 (en) | Compositions and methods for targeting, editing, or modifying genes | |
| WO2023225035A2 (en) | Compositions and methods for engineering cells | |
| EP4370676A2 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| EP4342983A1 (en) | Method for modifying cell | |
| WO2023233342A2 (en) | Gene-edited natural killer cells | |
| CA3246397A1 (en) | Compositions and methods for generating cells with reduced immunogenicity | |
| US20250388896A1 (en) | Composition and methods for transgene insertion | |
| WO2024233505A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| WO2024025908A2 (en) | Compositions and methods for genome editing | |
| WO2024037461A1 (zh) | 工程化免疫细胞及其制备方法 | |
| CN119451992A (zh) | 靶向gpc-3的嵌合抗原受体和表达其的免疫细胞用于治疗用途 | |
| CN118076728A (zh) | 用于疗法的工程细胞 | |
| HK40013246B (zh) | 用具有工程化穏定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法 |